Dimensional Fund Advisors
MGX icon

Dimensional Fund Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Dimensional Fund Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.1K Sell
12,797
-986
-7% -$1.53K ﹤0.01% 3210
2025
Q4 		$22.3K Buy
+13,783
New +$29.8K ﹤0.01% 3234

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors's MGX Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its Metagenomi Therapeutics (MGX) stake by 7.2% in Q1 2026, selling an estimated $1.53K and leaving 12,797 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3210.

Dimensional Fund Advisors first reported a position in MGX in Q4 2025 and has held it in 2 quarters since. The position peaked at $22.3K in Q4 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Dimensional Fund Advisors held 12,797 shares of Metagenomi Therapeutics worth $17.1K as of Q1 2026.
  • Dimensional Fund Advisors sold 986 Metagenomi Therapeutics shares in Q1 2026, an estimated $1.53K.
  • Metagenomi Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #3210 holding.
  • Dimensional Fund Advisors first reported a position in Metagenomi Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Dimensional Fund Advisors's Metagenomi Therapeutics position peaked at $22.3K in Q4 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.